🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Cara Therapeutics launches early-stage study of Korsuva in liver disease; shares up 2%

Published 02/28/2018, 10:50 AM
© Reuters.  Cara Therapeutics launches early-stage study of Korsuva in liver disease; shares up 2%
CARA
-
  • Dosing is underway in a Phase 1 study evaluating the safety and pharmacokinetics of Cara Therapeutics' (CARA +2.3%) Oral KORSUVA (difelikefalin) in patients with chronic liver disease (CLD). The open-label trial will enroll up to 60 subjects with CLD and up to 12 healthy patients for control.
  • Results will inform the design of a Phase 2 clinical trial in patients with moderate-to-severe CLD-associated pruritis.
  • KORSUVA is a peripherally acting kappa opioid receptor agonist that is also being developed for the treatment of acute and chronic pain. Its value proposition is opioid-like analgesia without the respiratory depression or intestinal tract inhibition (constipation).
  • Previously: Cara Therapeutics launches late-stage study of CR845 in CKD-aP (Jan. 31)
  • Now read: Marijuana Stocks That Could Outpace The Market In 2018


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.